Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Forxiga dapagliflozin regulatory update

Bristol-Myers Squibb said in its 1Q13 earnings statement that the China Food and Drug Administration accepted for review in January

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE